MENU
APR 22, 2019 12:00 AM PDT

Direct Oral Anti-Coagulant (DOAC) Measurement Focusing on Anti-Xa, and Recent DOAC Trial Updates

Sponsored by: Diagnostica Stago, Inc.
C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Chair and Professor, Medicine (primary) Professor, Clinical Epidemiology and Biostatistics (Associate) Leo Pharma Chair in Thromboembolism Research
    Biography
      Dr Crowther's research interests include improving the way we use current anticoagulant drugs. These include exploring established and novel interventions to mitigate bleeding, and studies of currently available anticoagulant drugs in high-risk patient populations. Dr Crowther's work also focusses on developing systematic reviews of key questions in Hematology and Thrombosis, and basing Guidelines on those reviews.

      Dr Crowther has more than 400 peer reviewed publications, was inducted into the Royal Society of Canada in 2017, and received the 2017 International Society of Thrombosis and Haemostasis BACH Investigator Recognition Award. He was one of 14 scientists from the Michael G. DeGroote School of Medicine at McMaster University cited by Clarivate Analytics on its Highly Cited Researchers list (formerly known as Thomson Reuter's annual publication of The World's Most Influential Scientific Minds).

      Dr Crowther is currently the Chair, Department of Medicine at McMaster University and holds the Leo Pharma Chair in Thromboembolism Research at McMaster University.

    Abstract

    Have you ever wondered about the impact of direct oral anticoagulants (DOACs) on routine coagulation assays and how patients on DOACs can be managed by the clinical laboratory? DOACs have been available for several years to treat atrial fibrillation patients at risk of stroke, as well as patients with venous thromboembolism (VTE). Though routine monitoring is not required for patients taking DOACs, screening or measurement assays could help in some emergency patient management situations. Dr Crowther’s webinar will cover this hot topic, which regularly impacts patients in critical care settings.

    Learning objectives:

    • Highlight recent clinical trials describing use of DOACs
    • Present situations for which DOAC monitoring can help in the picture of patient care
    • Review best practice with respect to DOAC measurement

     


    Show Resources
    You May Also Like
    JAN 23, 2020 9:00 AM PST
    C.E. CREDITS
    JAN 23, 2020 9:00 AM PST
    DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
    APR 07, 2020 8:00 AM PDT
    C.E. CREDITS
    APR 07, 2020 8:00 AM PDT
    DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
    MAY 08, 2020 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    MAY 08, 2020 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: May 8, 2020 TIME: 10:00am PT, 11:00am MT, 1:00pm ET The application of next generation sequencing to interrogate immune repertoires and methods in which these highly complex dataset...
    DEC 05, 2019 5:00 AM PST
    C.E. CREDITS
    DEC 05, 2019 5:00 AM PST
    DATE: December 5, 2019TIME: 5:00am PST, 8:00am EST The diagnosis of an active infection by the hepatitis B virus (HBV) relies on testing for the HBV surface antigen (HBsAg). Ov...
    APR 23, 2020 9:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    APR 23, 2020 9:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: April 23, 2020 Time: 9:00am PDT, 12:00pm EDT Analytical quality control refers to all those processes and procedures designed to ensure that the results of laboratory analysis are cons...
    OCT 31, 2019 9:00 AM PDT
    C.E. CREDITS
    OCT 31, 2019 9:00 AM PDT
    DATE: October 31, 2019TIME: 9:00am PDT, 12:00pm EDT INTRODUCTION: A major limitation for the development of 3D engineered tissues is the absence of viable and perfusable...
    Loading Comments...
    Show Resources